G2TT
来源类型Report
规范类型报告
DOIhttps://doi.org/10.7249/RRA788-1
来源IDRR-A788-1
Comparing Insulin Prices in the United States to Other Countries: Results from a Price Index Analysis
Andrew W. Mulcahy; Daniel Schwam; Nathaniel Edenfield
发表日期2020-10-06
出版年2020
页码33
语种英语
结论
  • Although the ratio of U.S. to other-country prices varied depending on the comparison country and insulin category, U.S. prices were always higher (often five to ten times higher) than those in other countries.
  • U.S. prices were higher for analog versus human insulins in nearly all comparison countries.
  • The overlap between the presentations of insulin sold in the United States and comparison countries was generally high, although there were differences in market shares across categories of insulin.
  • The United States was unusual among comparison countries in permitting distribution of several types of insulin over the counter. However, U.S. manufacturer prices were still much higher than those in comparison countries even in categories in which U.S. distribution is entirely over the counter.
  • Although the authors focused their analysis on manufacturer prices rather than on net prices after potential rebates, the analysis suggests that U.S. insulin prices would still have been considerably higher — about four times higher — than those in other countries even when accounting for potential rebates.
摘要

Insulin prices have increased dramatically over the past decade in the United States. In this report, the authors compare international prices for insulins using a price index approach. They describe the shares of volume and sales for all insulins and different categories of insulin (including insulin type and timing characteristics) in the United States and 32 comparison Organisation for Economic Co-operation and Development (OECD) countries in 2018. For the market basket of insulins sold in both the United States and comparison countries, the authors report ratios of U.S. insulin prices to insulin prices in other countries. They found that manufacturer prices in the United States were considerably higher (often five to ten times higher) than those in other OECD countries for all insulins combined and for different types of insulin. Although the authors focused their analysis on manufacturer prices rather than on net prices after potential rebates, the analysis suggests that U.S. insulin prices would still have been considerably higher — about four times higher — than those in other countries even when accounting for potential rebates.

目录
  • Chapter One

    Background and Analysis

  • Chapter Two

    Results

  • Chapter Three

    Summary of Findings

  • Appendix

    Exhibits

主题Diabetes ; Health Care Costs ; Pharmaceutical Drugs ; United States
URLhttps://www.rand.org/pubs/research_reports/RRA788-1.html
来源智库RAND Corporation (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/524242
推荐引用方式
GB/T 7714
Andrew W. Mulcahy,Daniel Schwam,Nathaniel Edenfield. Comparing Insulin Prices in the United States to Other Countries: Results from a Price Index Analysis. 2020.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
RAND_RRA788-1.pdf(736KB)智库出版物 限制开放CC BY-NC-SA浏览
1601983654359.jpg(6KB)智库出版物 限制开放CC BY-NC-SA缩略图
浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Andrew W. Mulcahy]的文章
[Daniel Schwam]的文章
[Nathaniel Edenfield]的文章
百度学术
百度学术中相似的文章
[Andrew W. Mulcahy]的文章
[Daniel Schwam]的文章
[Nathaniel Edenfield]的文章
必应学术
必应学术中相似的文章
[Andrew W. Mulcahy]的文章
[Daniel Schwam]的文章
[Nathaniel Edenfield]的文章
相关权益政策
暂无数据
收藏/分享
文件名: RAND_RRA788-1.pdf
格式: Adobe PDF
文件名: 1601983654359.jpg
格式: JPEG

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。